A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study(,)

PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol
Hlavní autoři: Jandial, Danielle A., Brady, William E., Howell, Stephen B., Lankes, Heather A., Schilder, Russell J., Beumer, Jan H., Christner, Susan M., Strychor, Sandra, Powell, Matthew A., Hagemann, Andrea R., Moore, Kathleen N., Walker, Joan L., DiSilvestro, Paul A., Duska, Linda R., Fracasso, Paula M., Dizon, Don S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706109/
https://ncbi.nlm.nih.gov/pubmed/28341300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.03.013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky